Safety, Tolerability, and Pharmacokinetics of NTM-1632, a Novel Mixture of Three Monoclonal Antibodies against Botulinum Toxin B
Jeffrey T. Guptill, Shruti M. Raja, Vern C. Juel, Emmanuel B. Walter, Michael Cohen‐Wolkowiez, Heather Hill, Eli A. Sendra, B. Hauser, Piper Jackson, Geeta K. Swamy
Abstract
). NTM-1632 demonstrated low immunogenicity with only a few treatment-emergent antidrug antibody responses in the low and middle dosing groups and none at the highest dose. NTM-1632 is well tolerated at the administered doses. The favorable safety, PK, and immunogenicity profile of NTM-1632 supports further clinical development as a treatment for BoNT/B intoxication and postexposure prophylaxis. (This study has been registered at ClinicalTrials.gov under identifier NCT02779140.).
Topics & Concepts
PharmacokineticsTolerabilityMonoclonal antibodyMedicinePharmacologyBotulinum toxinToxinAnesthesiaAntibodyAdverse effectImmunologyMicrobiologyBiologyBotulinum Toxin and Related Neurological DisordersNeurological disorders and treatmentsHereditary Neurological Disorders